Given the broad choice of treatments for some conditions, it is not likely that data is available from randomized control trials in which all possible treatments are compared directly. For instance, two particular treatments might never have been compared directly against each other, head-to-head, even though each of them may have been compared against a common comparator (control). While control treatment A may have been compared against active treatment B, and treatment A may have been compared against active treatment C, an indirect comparison on effectiveness can be made between treatments B and C – the two active treatments of interest. As a key part of comparative effectiveness research, network meta-analysis enables us to combine trials involving different sets of treatments, using a network of evidence, within a single analysis. This integrated and structured analysis incorporates all direct and indirect comparative evidence about treatments.
This brief tutorial highlights and illustrates the concepts and assumptions of network meta-analysis (homogeneity, transitivity, consistency) and provides attendees with important applicable information. Our speaker draws on his years of clinical experience to impart lessons and key insights to attendees looking to grow professionally add to their skill set.
Join our audio conference on March 31st with Joseph Cappelleri, Pfizer, Inc. To register, please visit our site http://info.fxtrans.com/network-meta-analysis-a-brief-tutorial/
The unmet need for newer analgesic compounds is a driving force behind today’s current pain research programs. Pain programs all come with a heightened risk, whether due to their subjective nature of response to treatment, high failure rates due to placebo response, and/or the use of subjective scales to determine symptomatic change. While you may have correctly selected the right pain and QOL PRO measures for your study, you still have many worries and concerns ahead of you. It is imperative to utilize your selected PRO scales correctly and consistently.
This presentation explores the most commonly used PRO measures in pain, such as the NRS-11 and Visual Analog Scale, as well as safety scales and quality of life measures. Each scale is discussed in detail, highlighting the intended design, appropriate usage, time parameters, and subject/site burden.
To join our audio conference, please register here: http://info.fxtrans.com/how-to-use-pro-pain-scales-consistently-and-effectively/
This audio conference presentation provides attendees with the tools to select the appropriate patient reported measures to reduce burden and redundancy, weighing the importance of managing expectations within the particular therapeutic area, with specific emphasis on reducing the placebo response. Attendees also learn why training on the protocol is not good enough. Study sites will always get training, but are they getting the right training, and do they have a thorough understanding of the procedures on the primary and secondary measures?
Our speaker draws on his depth of experience to explain why developing multiple training programs are essential for trial success. And lastly, attendees learn how to increase the subject’s ability to reliably understand and complete these patient reported measures. With careful and appropriate selection of PRO measures, detailed training programs, and continued oversight of your clinical trial, you can reduce your risk and promote success for your clinical trial. This audio conference shows you how.
Join us for our complementary conference on December 9th, presented by Nicholas Greco,
C3 Education and Research, Inc. Register here: http://info.fxtrans.com/selecting-and-using-the-right-pros-for-your-study/
How can large amounts of independent quantitative information on the same question come together in a coherent and meaningful manner? Many researchers have relied on meta-analysis to achieve such synthesis of evidence. “Meta-analysis” may be defined as the statistical analysis of data from multiple studies. A meta-analysis typically summarizes results and evaluates quantitatively sources of heterogeneity and bias. Meta-analysis is often accompanied by a systematic literature review, which encompasses an explicit and detailed description of how studies on a topic were identified and selected to answer a particular research question. Results of several similar studies identified with a systematic literature review can be quantitatively synthesized by means of meta-analysis to obtain a pooled estimate of the outcome of interest and the evaluation of heterogeneity.
This audio conference presentation centers around four related themes: 1) impetus for systematic literature reviews and meta-analysis, 2) basic steps to perform a meta-analysis and systematic literature review, 3) statistical methods of combining data, and 4) reporting and appraising of results. Concepts are motivated by instructive and real examples. This tutorial is intended to assist stakeholders of healthcare in making informed decisions in order to improve healthcare.
This presentation is designed to provide marketers, clinical scientists, C-suite executives and others with a solid understanding of how value is demonstrated in HEOR. Our speaker addresses central themes such as HEOR terminology, the things that matter to stakeholders, incremental cost-effectiveness, and budget impact models. Join us for this timely session as we share the information you need to understand HEOR and its growing importance in the field of healthcare. http://info.fxtrans.com/heor-what-marketing-scientists-and-the-c-suite-need-to-know/